Skip to content

Three Quick Facts: The Sage Group, ImmuPhama and Unite Group


Three things you need to know in the financial markets this morning from investment writer, Tony Cross.

The Sage Group

Slim pickings as is often the way for a Friday, but one heavyweight on the agenda today is Sage [LON:SGE]. The UK based software company published full year numbers which showed steady revenue increases but some margin erosion. The company has put aside a relatively small sum to account for bad debts arising off the back of COVID-19 and notes that even with the economic uncertainty that prevails right now, revenues for the coming year should increase by a further 3%-5%.


ImmuPhama [LON:IMM] has given investors a date for their diaries with news this morning that a meeting with the FDA has been confirmed for December 4th. This will allow its licensing partner to seek guidance from the regulator and also apply for conditional approval of a new drug to treat an auto-immune disease whilst phase 3 trials are underway. A further update has been promised as soon as news is released, but this clearly has the ability to drive sentiment.

Unite Group

There’s an update out from student accommodation providers Unite [LON:UTG], highlighting the fact they have secured a site in Paddington to build an 800 bed development subject to planning permissions. The note also includes details of how the current year is progressing, noting that 88% of all beds are let, down from 98% in the previous academic year. This, combined with rental arrears means that the anticipated reduction in rental income has been adjusted to a level of up to 20%, from a previously stated 10%-20% range. However the company believes students remain committed to studying away from home and this current episode can be overcome.

Sign up for three quick facts and more with our Free Daily Digest newsletter, every weekday morning.

Looking for great investing ideas? Sign up to our free newsletter.

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
CME Group
Back To Top